Rehap Investigators

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5573600/publications.pdf

Version: 2024-02-01

181 papers	3,584 citations	236612 25 h-index	161609 54 g-index
207 all docs	207 docs citations	207 times ranked	3489 citing authors

#	ARTICLE	IF	CITATIONS
1	Left Main Coronary Artery Stent Destructuring by a Pulmonary Artery Aneurysm. Cardiovascular Revascularization Medicine, 2022, 40, 246-248.	0.3	0
2	An openâ€label, doseâ€escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension. Pulmonary Circulation, 2022, 12, e12024.	0.8	8
3	Pulmonary thromboendarterectomy in chronic thromboembolic pulmonary hypertension: the Spanish experience. Annals of Cardiothoracic Surgery, 2022, 11, 151-160.	0.6	6
4	Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Scientific Reports, 2022, 12, 5289.	1.6	6
5	Management and prognosis of HIVâ€associated pulmonary arterial hypertension: 20 Years of evidence from the REHAP registry. Journal of Internal Medicine, 2022, 292, 116-126.	2.7	5
6	HipertensiÃ³n arterial pulmonar. Medicina ClÃnica, 2022, 158, 622-629.	0.3	11
7	The role of cardiopulmonary exercise test in identifying and monitoring pulmonary veno-oclusive disease. A case report. European Heart Journal - Case Reports, 2022, 6, ytac138.	0.3	0
8	Description of Two New Cases of AQP1 Related Pulmonary Arterial Hypertension and Review of the Literature. Genes, 2022, 13, 927.	1.0	5
9	Pulmonary arterial hypertension. Medicina ClÃnica (English Edition), 2022, 158, 622-629.	0.1	4
10	Clinical relevance of adding intravascular ultrasound to coronary angiography for the diagnosis of extrinsic left main coronary artery compression by a pulmonary artery aneurysm in pulmonary hypertension. Catheterization and Cardiovascular Interventions, 2021, 98, 691-700.	0.7	6
11	Portopulmonary hypertension: prognosis and management in the current treatment era â€“ results from the REHAP registry. Internal Medicine Journal, 2021, 51, 355-365.	0.5	30
12	Chronic thromboembolic pulmonary hypertension in Spain: a decade of change. Revista Espanola De Cardiologia (English Ed), 2021, 74, 384-392.	0.4	6
13	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220.	1.3	23
14	Radiological Findings in Multidetector Computed Tomography (MDCT) of Hereditary and Sporadic Pulmonary Veno-Occlusive Disease: Certainties and Uncertainties. Diagnostics, 2021, 11, 141.	1.3	6
15	Persistent Pulmonary Hypertension in Corrected Valvular Heart Disease: Hemodynamic Insights and Longâ€Term Survival. Journal of the American Heart Association, 2021, 10, e019949.	1.6	18
16	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. Expert Review of Respiratory Medicine, 2021, 15, 493-504.	1.0	2
17	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241.	1.3	13
18	From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?. Advances in Therapy, 2021, 38, 1860-1875.	1.3	3

#	ARTICLE	IF	CITATIONS
19	The role of cardiopulmonary exercise test in identifying pulmonary veno-occlusive disease. European Respiratory Journal, 2021, 57, 2100115.	3.1	5
20	Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE. Journal of Heart and Lung Transplantation, 2021, 40, S109.	0.3	0
21	Novel TNIP2 and TRAF2 Variants Are Implicated in the Pathogenesis of Pulmonary Arterial Hypertension. Frontiers in Medicine, 2021, 8, 625763.	1.2	13
22	Recent advances in the pharmacotherapy of pulmonary hypertension: practical considerations. Kardiologia Polska, 2021, 79, 386-392.	0.3	4
23	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2021, 384, 1204-1215.	13.9	224
24	HipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica en EspaÃ±a: unaÂdÃ©cada de cambio. Revista Espanola De Cardiologia, 2021, 74, 384-392.	0.6	9
25	Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) in a Real-World Clinical Setting: Insights from the EXPOSURE Study. , 2021, , .		1
26	PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic. Orphanet Journal of Rare Diseases, 2021, 16, 196.	1.2	11
27	Novel Genetic and Molecular Pathways in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease. Cells, 2021, 10, 1488.	1.8	17
28	FÃstula entre bronquio y arteria pulmonar. Una grave complicaciÃ³n de la angioplastia pulmonar en la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Revista Espanola De Cardiologia, 2021, 74, 548-549.	0.6	0
29	COVID-19 Experience and Pulmonary Arterial Hypertension: Do Earlier Theses and New Data Still Match?. Annals of the American Thoracic Society, 2021, 18, 1080-1081.	1.5	1
30	Potential Role of Natriuretic Response to Furosemide Stress Test During Acute Heart Failure. Circulation: Heart Failure, 2021, 14, e008166.	1.6	13
31	Selective Segmental Pulmonary Angiography: Anatomical, Technical and Safety Aspects of a Must-Learn Technique in Times of Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension. Journal of Clinical Medicine, 2021, 10, 3358.	1.0	2
32	Aneurisma gigante de la arteria pulmonar en hipertensiÃ³n arterial pulmonar. Archivos De Bronconeumologia, 2021, 57, 541.	0.4	0
33	Giant pulmonary artery aneurysm in pulmonary arterial hypertension. Archivos De Bronconeumologia, 2021, 57, 541.	0.4	0
34	Sex Differences in Chronic Thromboembolic Pulmonary Hypertension. Treatment Options over Time in a National Referral Center. Journal of Clinical Medicine, 2021, 10, 4251.	1.0	4
35	El papel de la genÃ©tica en la hipertensiÃ³n arterial pulmonar asociada con cardiopatÃas congÃ©nitas. Revista Espanola De Cardiologia, 2021, 74, 884-886.	0.6	2
36	The role of genetics in pulmonary arterial hypertension associated with congenital heart disease. Revista Espanola De Cardiologia (English Ed), 2021, 74, 884-886.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Complications associated with peripherally inserted central catheters and Hickmanâ„¢ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respiratory Medicine, 2021, 189, 106649.	1.3	0
38	Expanding the Evidence of a Semi-Dominant Inheritance in GDF2 Associated with Pulmonary Arterial Hypertension. Cells, 2021, 10, 3178.	1.8	12
39	Control clÃ¡nico en la EPOC: Â¿un nuevo objetivo terapÃ©utico?. Archivos De Bronconeumologia, 2020, 56, 68-69.	0.4	20
40	COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey. ERJ Open Research, 2020, 6, 00520-2020.	1.1	40
41	Effect of Coronavirus Disease 2019 in Pulmonary Circulation. The Particular Scenario of Precapillary Pulmonary Hypertension. Diagnostics, 2020, 10, 548.	1.3	21
42	Unexpected Favourable Course of Coronavirus Disease 2019 in Chronic Thromboembolic Pulmonary Hypertension Patients. Archivos De Bronconeumologia, 2020, 56, 749-752.	0.4	6
43	Feasibility of a Noninvasive Operability Assessment in Chronic Thromboembolic Pulmonary Hypertension under Real-World Practice. Diagnostics, 2020, 10, 855.	1.3	5
44	Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry. , 2020, , .		2
45	Characterization of rare ABCC8 variants identified in Spanish pulmonary arterial hypertension patients. Scientific Reports, 2020, 10, 15135.	1.6	19
46	Taponamiento cardiaco inverso en hipertensiÃ³n pulmonar grave. Medicina ClÃ¡nica, 2020, 154, 287.	0.3	0
47	CONTEMPORARY TREATMENT PATTERNS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: INSIGHT FROM THE OBSERVATIONAL EXPOSURE STUDY. Chest, 2020, 158, A2259-A2260.	0.4	0
48	Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study. , 2020, , .		0
49	Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study. BMC Pulmonary Medicine, 2020, 20, 154.	0.8	1
50	Clinical course of COVID-19 in pulmonary arterial hypertension patients. Revista Espanola De Cardiologia (English Ed), 2020, 73, 775-778.	0.4	15
51	Giant T Wave Inversion and Dyspnea in the Time of Coronavirus Pandemic. Circulation, 2020, 142, 906-909.	1.6	1
52	Heart Transplantation in a Distant Island Population: Accessibility and Outcomes in Patients From the Canary Islands Transplanted in Madrid. Transplantation, 2020, 104, 223-226.	0.5	1
53	Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. PLoS ONE, 2020, 15, e0232216.	1.1	21
54	Influence of long-standing pulmonary arterial hypertension and its severity on pulmonary artery aneurysm development. Heart and Vessels, 2020, 35, 1290-1298.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta. International Journal of Molecular Sciences, 2020, 21, 2509.	1.8	7
56	Customized Massive Parallel Sequencing Panel for Diagnosis of Pulmonary Arterial Hypertension. Genes, 2020, 11, 1158.	1.0	21
57	Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension. Journal of Clinical Medicine, 2020, 9, 448.	1.0	20
58	FRI0242â€…IMPACT OF PULMONARY ARTERIAL HYPERTENSION WITH OR WITHOUT INTERSTITIAL LUNG DISEASE ON SCLERODERMA: A RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA (RESCLE) AND PULMONARY ARTERIAL HYPERTENSION (REHAP) REGISTRIES. Annals of the Rheumatic Diseases, 2020, 79, 705.2-705.	0.5	0
59	Phenotype of patients with severe pulmonary hypertension secondary to chronic obstructive pulmonary disease: A multicentre study. , 2020, , .		0
60	Exercise capacity in patients with Pulmonary Arterial Hypertension: multicentric analysis of aerobic capacity and survival. , 2020, , .		0
61	Treatment of severe pulmonary hypertension secondary to chronic lung disease: A multicentre study. , 2020, , .		0
62	Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE. , 2020, , .		0
63	Atrial Fibrillation Surgical Ablation Long-term Outcome Prediction Just with One Lead of the Preoperative Surface Electrocardiogram. , 2020, , .		0
64	Novel Time-Frequency Features of the Fibrillatory Waves Improve Catheter Ablation Outcome Prediction of Persistent Atrial Fibrillation. , 2020, , .		0
65	Pretriscuspid shunt and Eisenmenger syndrome: a deadly combination. European Heart Journal, 2020, 41, .	1.0	0
66	Are there real differences between the treatment for young and elderly patients with chronic thromboembolic pulmonary hypertension?. European Heart Journal, 2020, 41, .	1.0	1
67	Pulmonary arterial hypertension in Spanish pediatric registry age: clinical characterization, management and survival. European Heart Journal, 2020, 41, .	1.0	0
68	Could we suspect pulmonary veno-oclussive disease with a cardiopulmonary exercise test?. European Heart Journal, 2020, 41, .	1.0	0
69	Cardiopulmonary exercise test could predict residual pulmonary hypertension after pulmonary endarterectomy. European Heart Journal, 2020, 41, .	1.0	0
70	Pulmonary hypertension and pregnancy. Is it time to reconsider recommendations in certain groups? Contemporary outcomes in a tertiary referral centre. European Heart Journal, 2020, 41, .	1.0	0
71	Idiopathic pulmonary hypertension in Spanish pediatric registry: clinical characterization, management, and risk factors for survival. European Heart Journal, 2020, 41, .	1.0	0
72	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Observational Study in a Referral Unit. Revista Espanola De Cardiologia (English Ed), 2019, 72, 224-232.	0.4	14

#	ARTICLE	IF	CITATIONS
73	Soporte circulatorio con oxigenador extracorpÃ³reo de membrana durante el embarazo en la enfermedad venooclusiva pulmonar. Revista Espanola De Cardiologia, 2019, 72, 174-175.	0.6	3
74	Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial. European Respiratory Journal, 2019, 54, 1901030.	3.1	33
75	Evaluation of a nurse-led intervention program in heart failure: A randomized trial. Medicina ClÃnica, 2019, 152, 431-437.	0.3	8
76	Sacubitril/valsartan eligibility and outcomes in the ESCâ€ŁORPâ€ŀHFA Heart Failure Longâ€ŀTerm Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€ŀHF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
77	Exercise Benefits in Pulmonary Hypertension. Journal of the American College of Cardiology, 2019, 73, 2906-2907.	1.2	5
78	Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary Circulation, 2019, 9, 1-3.	0.8	20
79	Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension: Final Data Cut from the EXPERT Registry. , 2019, , .		0
80	Safety of Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension: Final Data Cut from the EXPERT Registry. , 2019, , .		4
81	Vitamin D deficiency among patients with pulmonary hypertension. BMC Pulmonary Medicine, 2019, 19, 258.	0.8	13
82	Management of incidentally diagnosed pulmonary artery dissection in patients with pulmonary arterial hypertension. European Journal of Cardio-thoracic Surgery, 2019, 56, 210-212.	0.6	6
83	Frequency, Predictors, and Prognostic Impact of Pulmonary Artery Aneurysms in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2019, 123, 474-481.	0.7	14
84	Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play. Archivos De Bronconeumologia, 2019, 55, 102-103.	0.4	3
85	Characterization and regulation of wildâ€type and mutant TASKâ€1 two pore domain potassium channels indicated in pulmonary arterial hypertension. Journal of Physiology, 2019, 597, 1087-1101.	1.3	35
86	Real-life experience of inhaled iloprost for patients with pulmonary arterial hypertension: Insights from the Spanish REHAP registry. International Journal of Cardiology, 2019, 275, 158-164.	0.8	11
87	Extracorporeal Membrane Oxygenation Support During Pregnancy in Pulmonary Veno-occlusive Disease. Revista Espanola De Cardiologia (English Ed), 2019, 72, 174-175.	0.4	1
88	Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag. Archivos De Bronconeumologia, 2019, 55, 393-394.	0.4	1
89	Correlation between perceived quality of life among patients with Pulmonary Arterial Hypertension, the 6-minute walking test and the risk stratification. , 2019, , .		0
90	Outcome of pulmonary hypertension associated with respiratory disease. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). , 2019, , .		0
92	Role of right ventricular reverse remodeling in risk assessment of pulmonary hypertension. Journal of Heart and Lung Transplantation, 2018, 37, 182-183.	0.3	0
93	GuÃa de diagnÃ³stico y tratamiento de la hipertensiÃ³n pulmonar: resumen de recomendaciones. Archivos De Bronconeumologia, 2018, 54, 205-215.	0.4	26
94	Lung Transplantation in Pulmonary Hypertension: A Multidisciplinary Unit's Management Experience. Transplantation Proceedings, 2018, 50, 1496-1503.	0.3	12
95	Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. European Heart Journal, 2018, 39, 1255-1264.	1.0	166
96	Surrogate Endpoints for Pulmonary Hypertension Management and Trial Design. Journal of the American College of Cardiology, 2018, 71, 764-765.	1.2	1
97	SelecciÃ³n de lo mejor del aÃ±o 2017 en hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia, 2018, 71, 299-300.	0.6	0
98	Selection of the Best of 2017 in Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2018, 71, 299-300.	0.4	0
99	Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Summary of Recommendations. Archivos De Bronconeumologia, 2018, 54, 205-215.	0.4	30
100	Variable Expressivity of a Founder Mutation in the EIF2AK4 Gene in Hereditary Pulmonary Veno-occlusive Disease and Its Impact on Survival. Revista Espanola De Cardiologia (English Ed), 2018, 71, 86-94.	0.4	5
101	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. Seminars in Arthritis and Rheumatism, 2018, 47, 870-876.	1.6	7
102	Physical activity levels are low in patients with pulmonary hypertension. Annals of Translational Medicine, 2018, 6, 205-205.	0.7	19
103	Letter by Hernandez-Gonzalez et al Regarding Article, â€œPhenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertensionâ€. Circulation, 2018, 137, 2411-2412.	1.6	5
104	Possible pathophysiological role of vitamin D deficit in pulmonary arterial hypertension. , 2018, , .		1
105	Impact of treatment strategy in survival of patients with idiopathic pulmonary arterial hypertension. Real world evidence from Spanish National Pulmonary Hypertension Registry (REHAP). , 2018, , .		0
106	Enfermedad venooclusiva pulmonar y hemangiomatosis capilar pulmonar. Medicina ClÃnica, 2017, 148, 265-270.	0.3	10
107	Myocardial injury in severe heritable pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2017, 36, 818-820.	0.3	0
108	Benefits of skeletal-muscle exercise training in pulmonary arterial hypertension: The WHOLEi+12 trial. International Journal of Cardiology, 2017, 231, 277-283.	0.8	76

#	ARTICLE	IF	CITATIONS
109	The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Review of Respiratory Medicine, 2017, 11, 491-503.	1.0	55
110	Trends in Pulmonary Hypertension Over a Period of 30 Years: Experience From a Single Referral Centre. Revista Espanola De Cardiologia (English Ed), 2017, 70, 915-923.	0.4	7
111	Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Medicina ClÃ¬nica (English Edition), 2017, 148, 265-270.	0.1	2
112	Resultados de la tromboendarterectomÃa pulmonar en la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Medicina ClÃ¬nica, 2017, 149, 1-8.	0.3	7
113	Effects of an 8-month exercise intervention on physical capacity, NT-proBNP, physical activity levels and quality of life data in patients with pulmonary arterial hypertension by NYHA class. Data in Brief, 2017, 12, 37-41.	0.5	5
114	Left Main Extrinsic Compression in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2017, 70, 2459-2460.	1.2	3
115	Pulmonary endarterectomy outputs in chronic thromboembolic pulmonary hypertension. Medicina ClÃ¬nica (English Edition), 2017, 149, 1-8.	0.1	3
116	Respuesta. Medicina ClÃ¬nica, 2017, 149, 320-321.	0.3	0
117	Hemodynamic Effects of the Oral Prostacyclin (IP) Receptor Agonist Ralinepag in Pulmonary Arterial Hypertension. Chest, 2017, 152, A738.	0.4	0
118	Lung and heart-lung transplantation in pulmonary arterial hypertension. PLoS ONE, 2017, 12, e0187811.	1.1	11
119	Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. , 2017, , .		0
120	Global cardiac risk assessment in the Registry Of Pregnancy And Cardiac disease: results of a registry from the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 523-533.	2.9	113
121	Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2. Journal of Heart and Lung Transplantation, 2016, 35, S358-S359.	0.3	1
122	Fractional Flow Reserve-guided Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2016, 69, 863.	0.4	4
123	Molecular Analysis of BMPR2 , TBX4 , and KCNK3 and Genotype-Phenotype Correlations in Spanish Patients and Families With Idiopathic and Hereditary Pulmonary Arterial Hypertension. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1011-1019.	0.4	25
124	Founder Mutation C.3344C>t(p.Pro1115Leu) in the EIF2KA4 Gene in Iberian Romani Patients With Pulmonary Veno-Occlusive Disease: A Warning for our Daily Practice. Archivos De Bronconeumologia, 2016, 52, 444-445.	0.4	3
125	Fibrosing mediastinitis, an unusual clinical entity reminding chronic thromboembolic pulmonary hypertension. Medicina ClÃ¬nica (English Edition), 2016, 147, 130-131.	0.1	0
126	Hallazgo de la mutaciÃ³n fundadora C.3344C>t(p.Pro1115Leu) en el gen EIF2KA4 en pacientes ibÃ©ricos de etnia gitana con enfermedad veno-oclusiva pulmonar: una llamada de atenciÃ³n a nuestra prÃ¡ctica diaria. Archivos De Bronconeumologia, 2016, 52, 444-445.	0.4	4

#	ARTICLE	IF	CITATIONS
127	Angioplastia pulmonar guiada por reserva de flujo fraccional en hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Revista Espanola De Cardiologia, 2016, 69, 863.	0.6	2
128	Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. International Journal of Cardiology, 2016, 203, 938-944.	0.8	46
129	Use of Atrial Septostomy to Treat Severe Pulmonary Arterial Hypertension in Adults. Revista Espanola De Cardiologia (English Ed), 2016, 69, 78-81.	0.4	5
130	Comments on the 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2016, 69, 102-108.	0.4	3
131	Angioplastia pulmonar con balÃ³n en la hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica no operable. Experiencia inicial en EspaÃ±a en unaÂserie de 7 pacientes. Revista Espanola De Cardiologia, 2015, 68, 535-537.	0.6	21
132	Pregnancy in Women With Structural Heart Disease: Experience in a Centre. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1189-1190.	0.4	3
133	A founder EIF2AK4 mutation causes an aggressive form of pulmonary arterial hypertension in Iberian Gypsies. Clinical Genetics, 2015, 88, 579-583.	1.0	57
134	Balloon Pulmonary Angioplasty for Inoperable Patients With Chronic Thromboembolic Pulmonary Hypertension. Preliminary Experience in Spain in a Series of 7 Patients. Revista Espanola De Cardiologia (English Ed), 2015, 68, 535-537.	0.4	10
135	TromboendarterectomÃa pulmonar en 106 pacientes con hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Archivos De Bronconeumologia, 2015, 51, 502-508.	0.4	15
136	Predictive value of NT-proBNP combined with exercise capacity variables in pulmonary artery disease: Insights from a Spanish cohort. International Journal of Cardiology, 2015, 186, 32-34.	0.8	6
137	Pulmonary hypertension and congenital heart disease: An insight from the REHAP National Registry. International Journal of Cardiology, 2015, 184, 717-723.	0.8	80
138	Pulmonary Thromboendarterectomy in 106 Patients With Chronic Thromboembolic Pulmonary Hypertension. Archivos De Bronconeumologia, 2015, 51, 502-508.	0.4	10
139	Rationale and Design of a Randomized Controlled Trial Evaluating Whole Muscle Exercise Training Effects in Outpatients with Pulmonary Arterial Hypertension (WHOLEi+12). Cardiovascular Drugs and Therapy, 2015, 29, 543-550.	1.3	6
140	EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217.	1.2	59
141	Pulmonary Arterial Hypertension: Epidemiology and Registries. Advances in Pulmonary Hypertension, 2014, 13, 21-26.	0.1	5
142	Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. World Journal of Cardiology, 2014, 6, 495.	0.5	18
143	RÃ©plica a la Carta al Director â€œInfecciones por gram negativos (BGN) en pacientes con hipertensiÃ³n arterial pulmonar tratados con prostaciclinas intravenosasâ€. Archivos De Bronconeumologia, 2013, 49, 217-218.	0.4	0
144	Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 2013, 62, D51-D59.	1.2	432

#	ARTICLE	IF	CITATIONS
145	Reply to Letter to the Editor â€œInfections by Gram-Negative Bacilliin Patients with Pulmonary Arterial Hypertension Treated with Intravenous Prostacyclinâ€• Archivos De Bronconeumologia, 2013, 49, 217-218.	0.4	0
146	Calidad de vida relacionada con la salud en una cohorte nacional de pacientes con hipertensiÃ³n arterial pulmonar o hipertensiÃ³n pulmonar tromboembÃ³lica crÃ³nica. Archivos De Bronconeumologia, 2013, 49, 181-188.	0.4	38
147	Demythologizing pulmonary artery aneurysm: prevalence and associated complications in a large pulmonary arterial hypertension population. European Heart Journal, 2013, 34, P226-P226.	1.0	4
148	Assessment of exercise response in chronic thromboembolic pulmonary hypertension by cardiopulmonary exercise testing. European Heart Journal, 2013, 34, P3355-P3355.	1.0	0
149	The role of vascular obstruction site on pulsatile afterload in patients with pulmonary hypertension. European Heart Journal, 2013, 34, P285-P285.	1.0	0
150	Compression of the Left Main Coronary Artery by a Giant Pulmonary Artery Aneurysm. Circulation, 2013, 127, 1340-1341.	1.6	14
151	Survival in pulmonary hypertension in Spain: insights from the Spanish registry. European Respiratory Journal, 2012, 40, 596-603.	3.1	342
152	Alta incidencia de bacteriemia por bacilos gramnegativos en pacientes con hipertensiÃ³n pulmonar tratados con treprostinil por vÃa intravenosa. Archivos De Bronconeumologia, 2012, 48, 443-447.	0.4	21
153	613 Lung and Heart-Lung Transplantation in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. Results from the Spanish Registry. Journal of Heart and Lung Transplantation, 2012, 31, S211-S212.	0.3	0
154	Steroid Withdrawal During 5 Years Following Heart Transplantation, and the Relationship Between Steroid Dosage at 1-Year Follow-up and Complications During the Next 2 Years: Results From the RESTCO Study. Transplantation Proceedings, 2012, 44, 2631-2634.	0.3	6
155	Predictors of Pulmonary Hypertension in Patients With Endâ€Stage Heart Failure. Congestive Heart Failure, 2012, 18, 212-216.	2.0	5
156	A Health Economic Analysis Of Sitaxentan For The Treatment Of Pulmonary Arterial Hypertension In Europe. , 2011, , .		0
157	Induction treatment with monoclonal antibodies for heart transplantation. Transplantation Reviews, 2011, 25, 21-26.	1.2	9
158	Factores determinantes de la capacidad de ejercicio en pacientes con hipertensiÃ³n arterial pulmonar severa. Archivos De Bronconeumologia, 2011, 47, 10-16.	0.4	4
159	Giant pulmonary artery aneurysm in a patient with vasoreactive pulmonary hypertension: a case report. BMC Cardiovascular Disorders, 2011, 11, 64.	0.7	24
160	Iloprostâ€”different indications and different national experiences in treating pulmonary hypertension. Clinical Research in Cardiology Supplements, 2010, 5, 19-23.	2.0	0
161	Current Diagnostic and Prognostic Assessment of Pulmonary Hypertension. Revista Espanola De Cardiologia (English Ed), 2010, 63, 583-596.	0.4	8
162	Complications of Proximal Pulmonary Artery Aneurysms in Patients With Severe Pulmonary Arterial Hypertension. Revista Espanola De Cardiologia (English Ed), 2010, 63, 617-618.	0.4	5

#	ARTICLE	IF	CITATIONS
163	Complicaciones de los aneurismas proximales de arteria pulmonar en pacientes con hipertensiÃ³n pulmonar severa. Revista Espanola De Cardiologia, 2010, 63, 617-618.	0.6	11
164	EvaluaciÃ³n diagnÃ³stica y pronÃ³stica actual de la hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia, 2010, 63, 583-596.	0.6	21
165	Effect of Different Pharmacologic Agents to Reverse Severe Pulmonary Hypertension Among End-Stage Heart Failure Patients. Transplantation Proceedings, 2009, 41, 2477-2479.	0.3	19
166	Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Diseaseâ€“related Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2009, 28, 621-627.	0.3	37
167	EstÃ¡ndares asistenciales en hipertensiÃ³n pulmonar. Revista Espanola De Cardiologia, 2008, 61, 170-184.	0.6	26
168	Extracorporeal Membrane Oxygenation as a Bridge to Emergency Heart-Lung Transplantation in a Patient With Idiopathic Pulmonary Arterial Hypertension. Journal of Heart and Lung Transplantation, 2008, 27, 466-468.	0.3	78
169	562 Levosimendan for acute decompensated end-stage chronic heart failure: experience in a heart transplant programme. European Journal of Heart Failure, Supplement, 2007, 6, 130-130.	0.2	0
170	Transition From Prostacyclin to Bosentan in Five Patients With Severe Pulmonary Hypertension: the Switch Is Possible. Revista Espanola De Cardiologia (English Ed), 2006, 59, 737-739.	0.4	2
171	Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. European Journal of Heart Failure, 2005, 7, 1011-1016.	2.9	246
172	Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. European Journal of Heart Failure, 2004, 6, 615-617.	2.9	42
173	Efficacy of Oral Sildenafil as Rescue Therapy in Patients With Severe Pulmonary Arterial Hypertension Chronically Treated With Prostacyclin. Long-Term Results. Revista Espanola De Cardiologia (English) Tj ETQq1 1 0.784314 rgBT /Overlo		
174	Sildenafilo como sustituto de prostaciclina subcutÃ¡nea en la hipertensiÃ³n pulmonar. Archivos De Bronconeumologia, 2003, 39, 476-477.	0.4	2
175	Impact of diltiazem administration and cyclosporine levels on the incidence of acute rejection in heart transplant patients. Transplant International, 2003, 16, 676-680.	0.8	2
176	Steroid withdrawal in nonimmunologically selected heart transplant recipients. Transplantation Proceedings, 2002, 34, 164-165.	0.3	7
177	Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. Journal of Heart and Lung Transplantation, 2001, 20, 942-948.	0.3	102
178	Benefits of mycophenolate mofetil in cardiac transplant recipients with cyclosporine-induced nephropathy. Transplantation Proceedings, 1999, 31, 2515-2516.	0.3	8
179	Early cyclosporine blood levels impact the incidence of acute rejection and overall mortality in the first year after heart transplantation. Transplantation Proceedings, 1998, 30, 1671-1672.	0.3	0
180	Time Variability of Fibrillatory Waves Energy Predicts Long-Term Outcome of Atrial Fibrillation Concomitant Surgical Ablation. , 0, , .		0

#	ARTICLE	IF	CITATIONS
181	Catheter Ablation Outcome Prediction with Advanced Time-Frequency Features of the Fibrillatory Waves from Patients in Persistent Atrial Fibrillation. , 0, , .		0